10-Q: Jackson Acquisition II Q3: SPAC Nears Combination Deadline

Jackson Acquisition Company II reports Q3 2025 net income driven by trust account interest, as it continues its search for a healthcare business combination target ahead of its December 2026 deadline.

Summary

• Reported net income of $2,346,020 for the three months ended September 30, 2025, and $6,891,757 for the nine months ended September 30, 2025.
• The net income was primarily generated from $2,475,639 in interest earned on marketable securities held in the Trust Account for Q3 2025 and $7,356,734 for the nine months ended September 30, 2025.
• General and administrative costs amounted to $129,619 for Q3 2025 and $464,977 for the nine months ended September 30, 2025.
• Cash balance outside the Trust Account was $585,116 as of September 30, 2025, a decrease from $949,366 at December 31, 2024.
• Marketable securities held in the Trust Account increased to $240,215,212 as of September 30, 2025, from $232,858,478 at December 31, 2024.
• The company is a blank check company focused on identifying a Business Combination target in the healthcare services or healthcare technology industry.
• The deadline to complete an initial Business Combination is December 11, 2026, which is 24 months from the closing of its Initial Public Offering.

Sentiment

Score: 6

Explanation: The company is performing as expected for a pre-combination SPAC, generating interest income and managing administrative costs. The substantial Trust Account balance is positive, but the inherent risks of finding a suitable target and the approaching deadline introduce uncertainty. The geopolitical risks are external but noted.

Positives

• Generated significant interest income from the Trust Account: $2,475,639 for Q3 2025 and $7,356,734 for the nine months ended September 30, 2025.
• Maintained a substantial Trust Account balance of $240,215,212, providing a strong capital base for a future Business Combination.
• Management believes it has sufficient funds for working capital needs for at least one year from the issuance date of the financial statements.

Negatives

• Operating at a loss from core activities, with no operating revenues generated to date, relying solely on interest income.
• Cash balance outside the Trust Account decreased from $949,366 at December 31, 2024, to $585,116 at September 30, 2025.
• Incurring ongoing administrative costs ($10,000 per month) and a significant Business Combination Marketing Fee (up to $9,200,000) payable upon completion of a Business Combination.

Risks

• Inability to successfully effect a Business Combination within the Combination Period (by December 11, 2026), which would lead to liquidation.
• Geopolitical instability (Russia-Ukraine conflict, Israel-Hamas conflict) could lead to market disruptions, volatility, supply chain interruptions, and increased cyberattacks, adversely affecting the search for a target business.
• Proceeds deposited in the Trust Account could become subject to claims of the company's creditors, potentially reducing funds available for public shareholders.
• Public shareholders may be restricted from redeeming more than an aggregate of 15% of their shares without company consent if shareholder approval is sought for a Business Combination and redemptions are not conducted via tender offer rules.
• Rights will expire worthless if a Business Combination is not completed within the required time period, and holders will not receive any funds from the Trust Account or outside assets with respect to such rights.
• Potential for insufficient funds to operate the business prior to an initial Business Combination if actual costs exceed estimates.
• May need to obtain additional financing either to complete a Business Combination or because of significant redemptions of public shares.

Future Outlook

The company intends to use substantially all funds held in the Trust Account, net of taxes, to complete an initial Business Combination, primarily targeting high-quality businesses in healthcare services or healthcare technology. It expects to incur significant costs in pursuit of its acquisition plans and may need additional financing if its estimates of costs are less than actual amounts or if it becomes obligated to redeem a significant number of public shares upon completion of a Business Combination. The deadline for completing a Business Combination is December 11, 2026.

Management Comments

• "We intend to effectuate our Business Combination using cash derived from the proceeds of the Initial Public Offering and the sale of the Private Placement Units, our shares, debt or a combination of cash, shares and debt."
• "We expect to continue to incur significant costs in the pursuit of our acquisition plans."
• "We do not expect to generate any operating revenues until after the completion of our Business Combination."
• "Management believes that the funds which the Company has available following the completion of the initial public offering will enable it to sustain operations for a period of at least one year from the issuance date of these unaudited condensed financial statements."
• "We do not believe we will need to raise additional funds in order to meet the expenditures required for operating our business."

Industry Context

Jackson Acquisition Company II operates as a Special Purpose Acquisition Company (SPAC) focused on identifying a high-quality target business within the healthcare services or healthcare technology industry. This sector focus aligns with current trends in healthcare innovation and digital transformation. As a SPAC, its primary activity is the search for a suitable merger or acquisition candidate, rather than generating operational revenue. The company's performance is currently measured by its ability to preserve and grow its Trust Account assets through interest income, while managing administrative expenses, as it navigates a competitive SPAC market and the inherent challenges of identifying and closing a de-SPAC transaction.

Comparison to Industry Standards

• As a SPAC, Jackson Acquisition Company II's financial performance is primarily characterized by interest income from its Trust Account and general administrative expenses, rather than operational revenue or profit from a core business. This is standard for pre-combination SPACs.
• The target industry focus on healthcare services and technology is common among SPACs seeking high-growth, innovation-driven sectors.
• The 24-month completion window (December 11, 2026) is a typical timeframe for SPACs to complete a Business Combination, aligning with industry norms for these vehicles.
• The redemption value of Class A ordinary shares ($10.44 per share as of September 30, 2025) reflects the accumulation of interest in the Trust Account, which is a standard feature designed to protect public shareholders.

Corporate Governance

Related Party Transactions

• Promissory Note: An unsecured promissory note to the Sponsor, with $198,024 outstanding as of September 30, 2025. The note was amended on May 7, 2025, to be payable upon consummation of an initial Business Combination or upon liquidation.
• Administrative Services Agreement: An agreement with the Sponsor to pay $10,000 per month for office space and administrative and support services, with $97,000 owed as of September 30, 2025.
• Founder Shares: 5,750,000 Class B ordinary shares were issued to the Sponsor for $25,000. The Sponsor also transferred 200,000 Founder Shares to the company's officers and directors.
• Working Capital Loans: The Sponsor, its affiliates, or certain officers and directors may loan the company funds for transaction costs, potentially convertible into Units of the post-Business Combination entity. No amounts were outstanding as of September 30, 2025.

Stakeholder Impact

• Shareholders (Public): Entitled to redeem shares for a pro rata portion of the Trust Account (currently $10.44 per share) upon a Business Combination or liquidation if no combination is completed. Holders of rights receive 1/10th of a Class A share upon combination but risk their rights expiring worthless if no combination occurs.
• Sponsor: Holds Founder Shares and Private Placement Units, has agreed to waive redemption rights on Founder Shares in connection with a Business Combination, and liquidation rights if no combination is completed. May provide Working Capital Loans.
• Underwriters (Roth Capital Partners): Purchased Private Placement Units and are engaged as an advisor for a Business Combination, entitled to a Business Combination Marketing Fee of up to $9,200,000 upon consummation of a Business Combination.
• Creditors: Claims could potentially reduce funds in the Trust Account below the redemption value for public shareholders, though the Sponsor has agreed to indemnify the Trust Account against certain claims.

Next Steps

• Identify and evaluate target businesses, particularly in healthcare services or technology.
• Perform business due diligence on prospective target businesses.
• Structure, negotiate, and complete a Business Combination by December 11, 2026.
• Manage working capital and potentially seek additional financing if needed for a Business Combination or redemptions.

Key Dates

Recommendation

Jackson Acquisition Company II is a SPAC operating as expected, generating interest income while actively searching for a target. The Trust Account value per share is growing, offering a floor for public shareholders. However, the inherent uncertainty of completing a suitable Business Combination by the December 2026 deadline, coupled with geopolitical risks and the potential for significant redemptions, makes it a 'hold.' Investors are essentially holding cash-like assets with the speculative upside of a successful de-SPAC transaction, but also the risk of liquidation at or near the redemption value if no deal is found.

Keywords

SPAC, Jackson Acquisition Company II, JACS, 10-Q, Quarterly Report, Business Combination, Healthcare SPAC, Trust Account, Financial Results, SEC Filing, Blank Check Company, Merger Acquisition